author-photo

Hannah Asghari

University of South Florida

12

Papers

12

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Monoclonal Gammopathy of Unknown Significance, Smoldering Myeloma, and Plasmacytomas

2020
- Hannah Asghari
- Brandon Blue
Show All
- Source
- Cite
- Save
Citations (0)
Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia

2020 Leukemia & Lymphoma
- Hannah Asghari
- Jeffrey E. Lancet
Show All
- Source
- Cite
- Save
Citations (0)
Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)
RUNX1 Mutation is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia (AML) who Received Allogeneic Stem Cell Transplantation (allo-SCT)

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

2019 Blood
Show All
- Source
- Cite
- Save
Citations (4)
RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

2019 Blood
Show All
- Source
- Cite
- Save
Citations (4)